Sinane M., Grunberger Colin, Gentile L., Moriou C., Chaker V., Coutrot P., Guenneguez Alain, Poullaouec M. A., Connan S., Stiger-Pouvreau V., Zubia M., Fleury Y., Cérantola S., Kervarec N., Al-Mourabit A., Petek Sylvain, Voisset C. (2024). Potential of marine sponge metabolites against prions : bromotyrosine derivatives, a family of interest. Marine Drugs, 22 (10), p. 456 [18 p.].
Titre du document
Potential of marine sponge metabolites against prions : bromotyrosine derivatives, a family of interest
Année de publication
2024
Auteurs
Sinane M., Grunberger Colin, Gentile L., Moriou C., Chaker V., Coutrot P., Guenneguez Alain, Poullaouec M. A., Connan S., Stiger-Pouvreau V., Zubia M., Fleury Y., Cérantola S., Kervarec N., Al-Mourabit A., Petek Sylvain, Voisset C.
Source
Marine Drugs, 2024,
22 (10), p. 456 [18 p.]
The screening of 166 extracts from tropical marine organisms (invertebrates, macroalgae) and 3 cyclolipopeptides from microorganisms against yeast prions highlighted the potential of Verongiida sponges to prevent the propagation of prions. We isolated the known compounds purealidin Q (1), aplysamine-2 (2), pseudoceratinine A (3), aerophobin-2 (4), aplysamine-1 (5), and pseudoceratinine B (6) for the first time from the Wallisian sponge Suberea laboutei. We then tested compounds 1-6 and sixteen other bromotyrosine and bromophenol derivatives previously isolated from Verongiida sponges against yeast prions, demonstrating the potential of 1-3, 5, 6, aplyzanzine C (7), purealidin A (10), psammaplysenes D (11) and F (12), anomoian F (14), and N,N-dimethyldibromotyramine (15). Following biological tests on mammalian cells, we report here the identification of the hitherto unknown ability of the six bromotyrosine derivatives 1, 2, 5, 7, 11, and 14 of marine origin to reduce the spread of the PrPSc prion and the ability of compounds 1 and 2 to reduce endoplasmic reticulum stress. These two biological activities of these bromotyrosine derivatives are, to our knowledge, described here for the first time, offering a new therapeutic perspective for patients suffering from prion diseases that are presently untreatable and consequently fatal.
Plan de classement
Substances naturelles [035]
Description Géographique
POLYNESIE FRANCAISE ; WALLIS ET FUTUNA
Localisation
Fonds IRD [F B010092038]
Identifiant IRD
fdi:010092038
